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ABSTRACT
Using 2-trichloromethylquinazoline as scaffold, seven novel triazole-linked compounds have been synthesized using CuAAC
chemistry. The in vitro biological activity of four of the compounds on the Plasmodium falciparum chloroquine-sensitive strain
NF54 was then determined. The compounds which were tested showed moderate activity with 1.45 µM as the lowest inhibitory
concentration.
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1. Introduction
Each year malaria affects between 300 and 500 million people
and responsible for the death of around 2.5 million people.1 The
emergence of drug resistance in species of the genus Plasmodium
towards the frequently used drug molecules such as chloro-
quine necessitates the discovery of new molecules with novel
mechanisms of action.2 In the late 1970s it was determined that
thioquinazolines (1) (Fig. 1) have shown potent antimalarial
effects against chloroquine-resistant variants of the Plasmodium
species.3 In addition, other quinazoline-derived compounds
containing thiourea moieties (2) have been synthesized and
confirmed to have antiplasmodial activity.4 More recently, work
by Vanelle and co-workers5 on a substituted quinazoline
scaffold, namely the 2-trichloromethylquinazoline (3) (Fig. 1),
demonstrated promising antimalarial activity for a set of mole-
cules based on this particular scaffold.
The 1,2,3-triazole moiety is an attractive option to use as a
structural feature in medicinal chemistry as it is stable in acidic/
basic as well oxidative/reductive conditions.6 This heterocycle
also has a high dipole moment and affords the possibility of
forming hydrogen bonds with biomolecular targets.7 These
systems are also attracting attention as they are readily synthe-
sized by well-defined copper-catalyzed azide-alkyne cyclization
(CuAAC) methods.8,9 Of relevance to this paper is that in recent
years, the use of CuAAC and the incorporation of triazole into
drug-like molecules with potential antimalarial activity have
seen increasing popularity.10–14 In this publication, we have
designed and synthesized a small series of novel trichloro-
methylquinazolines (4) employing ‘click chemistry’ as a means
to introduce diversity into the side chain. The side chains
included unsubstituted aryl groups and some small heterocyclic
groups in order to give a starting point for this exploration. The
aryl groups were chosen as Vanelle and co-workers5 had used
the simpler quinazoline structure 3 with a variety of phenyl
groups and achieved micromolar activities against a variety of
strains of P. falciparum. The nitrogen-containing side chains were
all chosen as a variety of these ligands have been used in
quinolines again to good effect.
2. Results and Discussion
2.1. Synthesis
The synthesis of the quinazoline scaffold was based on the
procedure described by Vanelle and co-workers using a conven-
tional method,15 followed by a coupling with propargyl amine in
a solvent-free medium (Scheme 1)16 to obtain the amino-
propargylated scaffold (7) in good yield.
The next step required the synthesis of the substituted azides
necessary for the CuAAC reactions. To this end, the synthesis of
the azide side chains began with the double mesylation of ethyl-
ene glycol (8), followed by the addition of the azide functional
group on one side to from compound 10. Five different second-
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Figure 1 Structures containing the quinazoline scaffolds and the 1,2,3-
triazole linker (4). R1, R2 and R3 represent a wide variety of substituents.
ary amines (11–15) were then incorporated by displacing the
remaining mesylate group using standard SN2 chemistry
(Scheme 2).17 At this point it should be mentioned that the
spectra for all the azido compounds generated here compared
well with that published in the literature (see experimental
section for more details). In addition, the use of IR spectroscopy
provided additional evidence that the compounds contained an
azide functional group with a characteristic signal being seen at
~2100 cm–1.
Another two azide side chains with aryl side chains were syn-
thesized to determine whether an aromatic group is necessary
for good antimalarial activity, as set out in Scheme 3.18,19 It should
be noted that the target of the trichloromethylquinazolines has
not yet been established, so it is not clear whether a basic nitro-
gen in the side chain is necessary, as it is in chloroquinoline-
based molecules.20
With the alkyne (7) and azide starting materials (11–15, 17, 19)
in hand, the CuAAC reactions, were attempted using the well
established conditions.21 CuSO4 was utilized as the source of
Cu(II), along with the reducing agent sodium ascorbate, in a
protic solvent mixture such as MeOH/H2O or t-BuOH/H2O.
Unfortunately, under these conditions the desired products
failed to form, or were only obtained in very low yields, even
when using excess copper salt in one of the attempts. In addition,
the use of only MeOH or t-BuOH as solvent did not improve the
results. As it was noted that Dabiri et al. had obtained acceptable
yields using a Cu(OAc)2 salt as the Cu(II) source, this particular
copper salt was also tried in our reactions using the above-
mentioned solvent systems, but little or no improvements were
observed.22
Since the general conditions did not work out as anticipated,
an alternative method was tried. The copper catalyst was thus
changed to CuI and an aprotic solvent system was used, as
adapted per the reaction conditions described by Bernard et al.
(Scheme 4).23 In this approach, the yields obtained were signifi-
cantly higher and the starting material was almost completely
consumed. After optimizing the conditions for the click reaction
(Scheme 4), the results obtained for the seven azides are tabu-
lated in Table 1. Whilst we have not unequivocally determined
the source of the problem in the first reaction conditions, the
presence of Cu(II) in a protic solvent appears to favour the
formation of a copper complex(es) with (7), thus rendering it less
available or inactive for catalysis of the CuAAC reaction. The
CuAAC products (21–26) were readily purified by silica gel
column chromatography and were obtained in good to moder-
ate yields (52–82 %). The compounds were then fully character-
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Scheme 1
Synthesis of the aminopropargylated scaffold (7).
Scheme  2
Procedure for the synthesis of the azide side chains.
Scheme 3
Synthesis of the aromatic azides (17 and 19).
ized by NMR and other spectroscopic techniques (see experi-
mental section for details).
The synthesized triazoles were then subjected to in vitro test-
ing using the modified method of Trager and Jensen24 and
Makler and co-workers25 on the sensitive P. falciparum NF54
strain. A full dose–response was performed on all compounds to
determine the concentration inhibiting 50 % of parasite growth
(IC50 value) and the values are shown in Table 1. The results of the
in vitro assay against the chloroquine-sensitive strain were
mostly in the millimolar range, with compound 26 showing the
best activity. Testing out against a chloroquine-resistant strain
was not performed as it was thought unlikely that these mole-
cules would show substantially improved efficacy in the resis-
tant strain. This is because the proposed mechanism of action,
whilst not unequivocally established, is thought to be different
to that of chloroquine. The activities reported by Vanelle and
co-workers5 for similar compounds (cf. 3 with R = Ph, IC50 against
W2 strain was 8.0 µM) can be considered to be within a similar
range – low micromolar values. Noting that different strains of
the parasite cannot be compared directly. Absolute values of
activity for most of these compounds were not determined
directly because they were submitted alongside another
completely unrelated group of compounds which were substan-
tially more active. Expending further effort to determine the
efficacy of these compounds was not deemed worthwhile.
In conclusion, a small series of novel compounds has been syn-
thesized using a suitably aminopropargylated 2-trichloro-
methylquinazoline as a scaffold, and a CuAAC approach.
Furthermore, we report a CuAAC method capable of generating
the desired triazole-linked entities in the presence of coordinat-
ing nitrogen atoms. The problems we had in synthesizing the
final compounds were resolved, in part, by using the conditions
stated, and a protic solvent, but further work would need to
be carried out to investigate the optimum conditions for this
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Scheme 4
CuAAC synthesis of novel 2-trichloromethylquinazoline-based compounds.
Table 1 Products obtained from the CuAAC click reactions of alkyne (7) and the seven azides (11–15, 17, 19) using the procedure described in Scheme 4
and their activity against the sensitive strain of Plasmodium falciparum (see Experimental for the details of the bioassays).
Compound no. Yield IC50 (NF54) IC50 (NF54)
(ng mL–1) a (µM) a
20 60 % >1000 >2.3
21 75 % ND –
22 54 % >1000 >2.2
23 70 % ND –
24 82 % >1000 >2.3
25 52 % ND –
26 53 % 824.8 1.46
Reference Chloroquine 7.0 0.014
a ND = not determined.
reaction. Finally, the compounds were evaluated in terms of
their ability to inhibit the P. falciparum NF54 strain parasite, and
were found to demonstrate weak activity. It was not clear from
these results what modifications of the side chain would be
usefully made in order to improve efficacy as there was no
marked different between the aryl and heterocyclic side chains.
However, it can be noted that the inclusion of the triazole moiety
did not appear to have an effect on the efficacy of this class of
compounds and therefore can be used to introduce diversity in
the side chain. It may be worthwhile to determine if biological




Chemicals were purchased from commercial suppliers and
were used as supplied. Melting points were determined in open
capillary tubes with a Gallenkamp apparatus and are uncor-
rected. 1H and 13C NMR spectra were determined on a Varian
Unity Inova 300 MHz or 400 MHz spectrometer at Stellenbosch
University. Chemical shifts are given in d values referenced to
the solvent and are reported in parts per million. High-resolu-
tion mass spectrometry was performed by CAF (Central
Anaytical Facility) at Stellenbosch University using a Waters
Synapt G2 spectrometer. Silica Gel 60 was used for flash column
chromatography. The progress of the reactions was monitored
by thin layer chromatography on using Kieselgel 60 plates.
3.2. Biological Testing
The test samples were tested in triplicate on one or two sepa-
rate occasions against chloroquine-sensitive (CQS) strain of
Plasmodium falciparum (D10). Continuous in vitro cultures of
asexual erythrocyte stages of P. falciparum were maintained
using a modified method of Trager and Jensen (1976). Quantita-
tive assessment of antiplasmodial activity in vitro was deter-
mined via the parasite lactate dehydrogenase assay using a
modified method described by Makler (1993). The test samples
were prepared to a 20 mg mL–1 stock solution in 100 % DMSO
and sonicated to enhance solubility. Samples were tested as a
suspension if not completely dissolved. Stock solutions were
stored at –20 °C. Further dilutions were prepared on the day of
the experiment. Chloroquine (CQ) was used as the reference
drug in all experiments. A full dose–response was performed for
all compounds to determine the concentration inhibiting 50 % of
parasite growth (IC50-value). Test samples were tested at a start-
ing concentration of 100 µg mL–1, which was then serially diluted
twofold in complete medium to give 10 concentrations; with the
lowest concentration being 0.2 µg mL–1. The same dilution tech-
nique was used for all samples. The highest concentration of
solvent to which the parasites were exposed to had no measur-
able effect on the parasite viability (data not shown). The
IC50-values were obtained using a non-linear dose–response
curve fitting analysis via Graph Pad Prism v.4.0 software.
3.3. Synthesis of Compounds
4-Chloro-2-trichloromethylquinazoline (6)
PCl5 (3.90 g, 18.7 mmol) and POCl3 (9.4 mL, 37 mmol) were
added to 2-methylquinazolin-4-one (0.50 g, 3.1 mmol) at 0 °C.
The mixture was then heated to reflux and stirred for 24 hours.
After cooling, the solution was diluted with CHCl3 (30 mL) and
ultra-sound was used to completely dissolve the reaction
product. The solution was then added to a beaker of ice and
alkalinized with dry NaHCO3 (180 g) while stirring. Alkalinity of
the water layer was confirmed with a universal pH indicator.
The solution was filtered to remove the salt and the solution was
extracted with CHCl3 (50 mL). The brown organic layer was
dried over anhydrous MgSO4, which was removed by filtration
and the filtrate concentrated under vacuum. Purification of the
brown solid was performed by flash chromatography with
CH2Cl2-petroleum ether (1:1) as eluent to give the product as
white powder (0.63 g, 72 % yield). Mp 126 °C (neat); IR (ATR):
1558 (m, aromatic), 775 cm–1 (s, CCl3);
1H NMR (CDCl3, 300 MHz,
25 °C): d = 7.87 (ddd, J = 8.3, 7.0 and 1.2 Hz, 1H, CH), 8.09 (ddd,
J = 8.5, 7.0 and 1.4 Hz, 1H, CH), 8.27 (ddd, J = 8.5, 1.2 and 0.7 Hz,
1H, CH), 8.34 (ddd, J = 8.4, 1.4 and 0.7 Hz, 1H, CH); 13C NMR
(CDCl3, 75.5 MHz, 25 °C): d = 95.9 (C), 122.9 (C), 125.9 (C), 129.7
(C), 130.6 (C), 135.9 (C), 150.1 (C), 159.9 (C), 164.0 (C). The spectro-
scopic data were in agreement with reported data.8
N-(Prop-2-yn-1-yl)-2-(trichloromethyl)quinazolin-4-amine (7)
Propargylamine (0.053 mL, 1.6 mmol) was added dropwise
onto 6 (0.15 g, 0.52 mmol). The solvent-free reaction mixture was
then stirred at rt for 5 min. The crude residue was then extracted
with CH2Cl2. The organic layer was washed with water (3 ×
15 mL), dried over anhydrous MgSO4, filtered and concentrated
under vacuum. Chromatography with CH2Cl2 as eluent
afforded the desired product (7) as white powder (0.14g, 93 %
yield). Mp 103 °C (neat); IR (ATR): 3333 (w, NH), 2925 (w, CH),
2161 (w, alkyne), 1584 (m, aromatic), 1347 (m, aryl–NH), 764 cm–1
(s, CCl3);
1H NMR (CDCl3, 300 MHz, 25 °C): d = 8.04–8.01 (m, 1H,
CH), 7.87–7.83 (m, 1H, CH), 7.82–7.79 (m, 1H, CH), 7.62–7.57 (m,
1H, CH), 6.07 (br s, 1H, NH), 4.58 (dd, J = 5.0 and 2.6 Hz, 2H, CH2),
2.33 (t, J = 2.56 Hz, 1H, CH); 13C NMR (CDCl3, 75.5 MHz, 25 °C):
d = 31.4 (C), 72.4 (C), 79.3 (C), 97.7 (C), 113.4 (C), 120.6 (C), 127.8
(C), 129.7 (C), 133.5 (C), 149.2 (C), 159.7 (C), 161.0 (C).
HRMS–ES+: m/z [M+H]+ calcd for C12H9N3Cl3: 299.9862; found:
299.9858.
Ethan-1,2-diyl Dimethanesulfonate (9)
MsCl (7.8 mL, 101.0 mmol) was added dropwise to a solution of
ethylene glycol (2.55 mL, 45.8 mmol), CH2Cl2 (45 mL) and Et3N
(12.8 mL, 91.6 mmol) while under ice cooling. The cloudy white
solution was stirred for 1 h at 0 °C and then overnight at rt. The
precipitate was then filtered off and the filtrate concentrated,
after which it was subjected to purification on a silica gel column
with 3:7 petroleum ether: EtOAc as eluent, to afford the product
(9) as slightly yellow clear oil (8.94 g, 89 % yield). IR (ATR): 1352
(s, S=O), 1173 cm–1 (s, sulfonate ester); 1H NMR (CDCl3,
400 MHz, 25 °C): d = 4.41 (s, 4H, CH2), 3.04 (s, 6H, CH3);
13C NMR
(CDCl3, 100 MHz, 25 °C): d = 67.0 (2C), 35.3 (2C). The spectro-
scopic data were in agreement with reported data.10
2-Azidoethyl Methanesulfonate (10)
Compound 9 (8.90 g, 40.8 mmol) and CH3CN (75 mL) was
added to a round bottom flask. NaN3 (2.65 g, 40.8 mmol) was
then added and the solution heated at refluxed (60 °C) for 22 h.
The cloudy mixture was filtered and the solvent was removed
from the filtrate, after which it was subjected to purification on a
silica column with 3:7 EtOAc:petroleum ether to afford the
desired product (10) as clear oil (3.03 g, 40 % yield). IR (ATR): 2136
(s, azide), 1347 (s, S=O), 1163 cm–1 (s, sulfonate ester); 1H NMR
(CDCl3, 400 MHz, 25 °C): d = 4.29 (t, J = 4.9 Hz, 2H, CH2), 3.55 (t,
J = 5.0 Hz, 2H, CH2), 3.05 (s, 3H, CH3);
13C NMR (CDCl3, 100 MHz,
25 °C): d = 66.0 (C), 48.0 (C), 35.8 (C). The spectroscopic data were
in agreement with reported data.10
General Procedure for the Coupling of the Amines with
2-Azidoethyl Methanesulfonate (10)
Compound 10 (1 eq.) and Et3N (2.1 eq.) were first added to
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CH3CN (8 mL). The amine (2 eq.) was then added to the solution
and the reaction solution was subsequently heated at reflux for
18 h under N2. The mixture was concentrated and purified on a
silica column using EtOAc as the eluent, to give the correspond-
ing products as described below.
4-(2-Azidoethyl)morpholine (11)
Orange oil (0.376 g, 83 % yield). IR (ATR): 2093 (s, azide),
1276 cm–1 (s, ether); 1H NMR (CDCl3, 400 MHz, 25 °C): d =
3.73–3.71 (m, 4.84H, CH2), 3.35 (d, J = 6.4 Hz, 2H, CH2), 2.59 (d, J =
6.0 Hz, 2H, CH2), 2.51–2.49 (m, 4.84H, CH2);
13C NMR (CDCl3,
100 MHz, 25 °C): d = 67.1 (C), 57.8 (2C), 53.8 (2C), 48.1 (C). The
spectroscopic data were in agreement with reported data.26
1-(2-Azidoethyl)piperidine (12)
Orange yellow oil (0.352 g, 78 % yield). IR (ATR): 2096 cm–1 (s,
azide); 1H NMR (CDCl3, 400 MHz, 25 °C): d = 3.28 (t, J = 6.3 Hz,
2H, CH2), 2.49 (t, J = 6.3 Hz, 2H, CH2), 2.46–2.40 (m, 4H, CH2),
1.62–1.56 (m, 4H, CH2), 1.46.–1.40 (m, 2H, CH2);
13C NMR (CDCl3,
100 MHz, 25 °C): d = 56.7 (C), 53.6 (2C), 47.4 (C), 24.8 (2C), 23.2
(C). The spectroscopic data were in agreement with reported
data.27
1-(2-Azidoethyl)pyrrolidine (13)
Orange oil (0.214 g, 63 % yield). IR (ATR): 2093 cm–1 (s, azide);
1H NMR (CDCl3, 400 MHz, 25 °C): d = 3.40 (t, J = 6.4 Hz, 2H,
CH2), 2.69 (t, J = 6.4 Hz, 2H, CH2), 2.58–2.55 (m, 4H, CH2),
1.81–1.78 (m, 4H, CH2);
13C NMR (CDCl3, 100 MHz, 25 °C): d =
56.0 (C), 54.4 (2C), 50.4 (C), 23.7 (2C). The spectroscopic data were
in agreement with reported data.28
2-Azido-N,N-dibenzylethanamine (14)
Viscous orange oil (0.316 g, 73 % yield). Mp 43 °C; IR (ATR):
2089 (s, azide), 1493 cm–1 (m, aromatic); 1H NMR (CDCl3,
300 MHz, 25 °C): d = 7.42–7.24 (m, 10H, CH), 3.65 (s, 4H, CH2),
3.26 (t, J = 6.1 Hz, 2H, CH2), 2.71 (t, J = 6.1 Hz, 2H, CH2);
13C NMR
(CDCl3, 75.5 MHz, 25 °C): d = 138.0 (2C), 127.8 (4C), 127.3 (4C),
126.1 (2C), 57.8 (C), 52.0 (C), 48.2 (C); HRMS–ES+: m/z [M+H]+
calcd for C16H18N4: 267.161; found: 267.161.
2-Azido-N,N-diethylethanamine (15)
Yellow oil (0.198 g, 57 % yield). IR (ATR): 2092 cm–1 (s, azide);
1H NMR (CDCl3, 400 MHz, 25 °C): d = 3.29 (t, J = 6.3 Hz, 2H, CH2),
2.64 (t, J = 6.3 Hz, 2H, CH2), 2.56 (q, J = 7.1 Hz, 4H, CH2), 1.03 (t,
J = 7.1 Hz, 6H, CH3);
13C NMR (CDCl3, 100 MHz, 25 °C): d = 52.3
(C), 49.7 (C), 47.4 (2C), 12.0 (2C). The spectroscopic data were in
agreement with reported data.27
Phenyl Azide (17)
Aniline (0.25 mL, 2.8 mmol) was suspended in H2O (2 mL).
After addition of concentrated H2SO4 (0.56 mL, 10.2 mmol) un-
der icebath cooling and stirring, a solution of NaNO2 (0.211 g,
3.05 mmol) in H2O (1.24 mL) was added dropwise. Hexane
(4 mL) was added, followed by dropwise addition of a solution
of NaN3 (0.15 g, 2.8 mmol) in water (1 mL). After stirring for 2 h,
the product was extracted with CH2Cl2 (20 mL) and washed with
water (20 mL). The organic layer was separated, dried over
anhydrous MgSO4, filtered and concentrated under reduced
pressure to give a pungent yellow liquid as product, which
was used in the next step without further purification (0.33 g,
98 % yield). 1H NMR (CDCl3, 300 MHz, 25 °C): d = 7.42–7.35
(m, 2H, CH), 7.20–7.14 (m, 1H, CH), 7.08–7.04 (m, 2H, CH);
13C NMR (CDCl3, 75.5 MHz, 25 °C): d = 140.1 (C), 129.9 (2C), 125.0
(2C), 119.2 (C). The spectroscopic data were in agreement with
reported data.18
Benzyl azide (19)
To a stirred solution of benzylbromide (1.0 mL, 8.8 mmol) in a
water/acetone mixture (1:4, 50 mL), NaN3 (0.856 g, 13.2 mmol)
was added. The resulting suspension was stirred at RT for 24 h.
CH2Cl2 (30 mL) was added to the mixture and the organic layer
was separated. The aqueous layer was extracted with CH2Cl2
(3 × 10 mL) and the combined organic layers were dried over
MgSO4. The solvent was removed under reduced pressure to
offer the product as orange yellow pungent oil, which was used
in the next step without further purification (1.030 g, 97 % yield).
1H NMR (CDCl3, 300 MHz, 25 °C): d = 7.25–7.43 (m, 5H, CH), 4.35
(s, 2H, CH2);
13C NMR (CDCl3, 75.5 MHz, 25 °C): d = 135.5 (C),
129.3 (2C), 128.3 (2C), 128.2 (C), 54.8 (C). The spectroscopic data
were in agreement with reported data.19
General Procedure for the CuAAC Reaction with the Azides
(11–15, 17, 19)
Scaffold 7 (1 eq.) and the azide (~1.1 eq.) were dissolved in
CH3CN (1 mL). Et3N (1.2 eq.) was then added to the solution,
followed by the addition of CuI (0.1 eq.). The mixture was then
stirred for 24 h at RT or until completion by monitoring the
progress of the reaction by TLC. On completion, the mixture was
concentrated and diluted with DCM (20 mL), which was washed
with saturated NH4Cl solution (3 × 15 mL). The organic layer
was separated, dried over anhydrous MgSO4 and concentrated,
after which the residue was subjected to purification on a silica
column using CH2Cl2 as eluent and then with 5 % MeOH to
afford the corresponding triazoles described below.
N-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-2-(trichloromethyl)
quinazolin-4-amine (20)
Cream solid (0.035 g, 60 % yield). Mp 187 °C (dec); IR (ATR):
3232 (w, azole), 1259 (m, CH2), 797 cm
–1 (m, CCl3);
1H NMR
(CDCl3, 400 MHz, 25 °C): d = 7.91 (dd, J = 8.4, 0.7 Hz, 1H, CH),
7.88 (d, J = 8.3 Hz, 1H, CH), 7.85 (s, 1H, CH), 7.74 (ddd, J = 8.3, 7.1,
1.2 Hz, 1H, CH), 7.48–7.43 (m, 1H, CH), 7.37–7.34 (m, 3H, CH),
7.29–7.26 (m, 2H, CH), 5.48 (s, 2H, CH2), 4.93 (d, J = 5.7 Hz, 2H,
CH2);
13C NMR (CDCl3, 100 MHz, 25 °C): d = 160.9 (C), 160.8 (C),
160.5 (C), 149.1 (C), 134.2 (C), 133.5 (C), 129.5 (C), 129.4 (2C), 129.2
(C), 128.7 (2C), 127.8 (C), 124.0 (C), 121.5 (C), 114.2 (C), 54.6 (C),
36.5 (C), CCl3 not detected; HRMS–ES+: m/z [M+H]
+ calcd for
C19H15Cl3N6: 433.0502; found: 433.0506.
N-[(1-Phenyl-1H-1,2,3-triazol-4-yl)methyl]-2-(trichloromethyl)
quinazolin-4-amine (21)
Cream solid (0.126 g, 75 % yield). Mp 195 °C (dec); IR (ATR):
3286 (w, azole), 2918 (w, CH), 1582 (m, aromatic), 1050 (m,
alkene), 757 cm–1 (s, CCl3);
1H NMR (CDCl3, 300 MHz, 25 °C): d =
7.98–7.93 (m, 3H, CH), 7.79–7.70 (m, 3H, CH), 7.57–7.41 (m, 4H,
CH), 5.09 (d, J = 5.7 Hz, 2H, CH2);
13C NMR (CDCl3, 75.5 MHz,
25 °C): d = 160.8 (C), 160.5 (C), 149.1 (C), 137.1 (C), 133.5 (C), 130.0
(2C), 129.5 (C), 129.1 (C), 127.8 (C), 126.1 (C), 122.5 (C), 121.5 (C),
119.3 (2C), 114.1 (C), 35.3 (C), CCl3 not detected; HRMS–ES+: m/z
[M+H]+ calcd for C18H14N6Cl3: 419.0346; found: 419.0345.
N-({1-[2-(Piperidin-4-yl)ethyl]-1H-1,2,3-triazol-4-yl}methyl)-
2-(trichloromethyl)quinazolin-4-amine (22)
Cream solid (0.109 g, 60 % yield). Mp 172 °C (dec); IR (ATR):
3235 (m, NH), 2923 (s, CH2), 1576 (m, aromatic), 767 cm
–1 (m,
CCl3);
1H NMR (CDCl3, 300 MHz, 25 °C): d = 8.06 (s, 1H, CH),
7.93–7.91 (m, 2H, CH), 7.76–7.71 (m, 1H, CH), 7.48–7.42 (m, 1H,
CH), 4.99 (d, J = 5.6 Hz, 2H, CH2), 4.48 (t, J = 6.5 Hz, 2H, CH2), 2.83
(t, J = 6.5 Hz, 2H, CH2), 2.49–2.46 (m, 4H, CH2), 1.60–1.53 (m, 4H,
CH2), 1.46–1.40 (m, 2H, CH2);
13C NMR (CDCl3, 75.5 MHz, 25 °C):
d = 161.0 (C), 160.4 (C), 149.1 (C), 144.7 (C), 133.4 (C), 129.4 (C),
127.7 (C), 124.6 (C), 121.6 (C), 114.1 (C), 97.4 (C), 58.2 (C), 54.7 (2C),
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47.8 (C), 36.5 (C), 25.7 (2C), 24.0 (C); HRMS–ES+: m/z [M+H]+
calcd for C19H22Cl3N7: 454.1081; found: 454.1078.
N-({1-[2-(Morpholin-4-yl)ethyl]-1H-1,2,3-triazol-4-yl}methyl)-
2-(trichloromethyl)quinazolin-4-amine (23)
Cream solid (0.128 g, 70 % yield). 168 °C (dec); IR (ATR): 3227 (w,
NH), 2920 (s, CH2), 1575 (w, aromatic), 765 cm
–1 (w, CCl3);
1H NMR
(CDCl3, 300 MHz, 25 °C): d = 8.07 (s, 1H, CH), 7.94–7.90 (m, 2H,
CH), 7.74 (ddd, J = 8.3, 7.0, and 1.3 Hz, 1H, CH), 7.45 (ddd, J = 8.3,
7.1, 1.2 Hz, 1H, CH), 4.99 (d, J = 5.8 Hz, 2H, CH2), 4.45 (t, J =
6.4 Hz, 2H, CH2), 3.67–3.64 (m, 4H, CH2), 2.81 (t, J = 6.4 Hz, 2H,
CH2), 2.49–2.46 (m, 4H, CH2);
13C NMR (CDCl3, 75.5 MHz, 25 °C):
d = 160.9 (C), 160.5 (C), 149.1 (C), 144.7 (C), 133.4 (C), 129.4 (C),
127.7 (C), 124.5 (C), 121.6 (C), 114.1 (C), 67.0 (2C), 58.0 (C), 53.7
(2C), 47.7 (C), 36.5 (C), CCl3 not detected; HRMS–ES+: m/z
[M+H]+ calcd for C18H20Cl3N7O: 456.0873; found: 456.0875.
N-({1-[2-(Pyrrolidin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl}methyl)-
2-(trichloromethyl)quinazolin-4-amine (24)
Cream solid (0.119 g, 82 % yield). 155 °C (dec); IR (ATR): 3333
(m, NH), 3062 (m, CH2), 2003 cm
–1 (m, azole); 1H NMR (CDCl3,
300 MHz, 25 °C): d = 8.17 (s, 1H, CH), 7.99 (d, J = 7.9 Hz, 1H, CH),
7.88 (d, J = 8.3 Hz, 1H, CH), 7.71–7.66 (m, 1H, CH), 7.36 (t, J =
7.4 Hz, 1H, CH), 4.98 (s, 2H, CH2, 4.45 (t, J = 6.3 Hz, 2H, CH2),
2.97–2.92 (m, 2H, CH2), 2.61–2.51 (m, 4H, CH2), 1.83–1.73 (m, 4H,
CH2);
13C NMR (CDCl3, 75.5 MHz, 25 °C): d = 160.9 (C), 160.5 (C),
149.0 (C), 144.7 (C), 133.2 (C), 129.1 (C), 127.5 (C), 124.6 (C), 122.0
(C), 114.2 (C), 98.6 (C), 55.6 (C), 54.2 (2C), 49.6 (C), 36.2 (C), 23.7




Cream solid (0.042 g, 52 % yield). 148 °C (dec); IR (ATR): 3333
(m, NH), 2148 (m, azole), 1965 cm–1 (m, aromatics); 1H NMR
(CDCl3, 300 MHz, 25 °C): d = 8.08 (s, 1H, CH), 7.95–7.91 (m, 2H,
CH), 7.77–7.71 (m, 1H, CH), 7.48–7.42 (m, 1H, CH), 4.98 (d, J =
5.5 Hz, 2H, CH2), 4.39 (t, J = 6.4 Hz, 2H, CH2), 2.88 (t, J = 6.4 Hz,
2H, CH2), 2.54 (q, J = 7.1 Hz, 4H, CH2), 0.94 (q, J = 7.1 Hz, 6H,
CH3);
13C NMR (CDCl3, 75.5 MHz, 25 °C): d = 161.0 (C), 160.5 (C),
149.1 (C), 140.2 (C), 133.4 (C), 129.4 (C), 127.6 (C), 124.8 (C), 121.7
(C), 114.2 (C), 52.9 (C), 49.2 (C), 47.5 (2C), 36.4 (C), 11.9 (2C), CCl3




Cream solid (0.092 g, 53 % yield). 167 °C (dec); IR (ATR): 3207 (s,
NH), 2237 (m, azole), 1580 cm–1 (w, aromatics); 1H NMR (CDCl3,
300 MHz, 25 °C): d = 8.00–7.97 (m, 2H, CH), 7.81–7.76 (m, 2H,
CH), 7.49–7.44 (m, 1H, CH), 7.30–7.18 (m, 10H, CH), 4.98 (d, J =
5.7 Hz, 2H, CH2), 4.34 (t, J = 6.3 Hz, 2H, CH2), 3.64 (s, 4H, CH2),
2.98 (t, J = 6.3 Hz, 2H, CH2);
13C NMR (CDCl3, 75.5 MHz, 25 °C):
d = 161.5 (C), 160.4 (C), 149.1 (C), 138.7 (2C), 133.4 (C), 129.4 (C),
128.9 (4C), 128.5 (4C), 127.7 (C), 127.4 (2C), 121.6 (C), 114.7 (C),
59.1 (2C), 53.4 (C), 49.0 (C), 36.4 (C), CCl3 not detected;
HRMS–ES+: m/z [M+H]+ calcd for C28H26Cl3N7: 566.1394; found:
566.1391.
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